Immune-Mediated Inflammatory Diseases and Cancer - a dangerous liaison.

Immune-Mediated Inflammatory Diseases biologic therapy immune dysregulation immunosuppression inflammation malignancy

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 22 05 2024
accepted: 29 08 2024
medline: 3 10 2024
pubmed: 3 10 2024
entrez: 3 10 2024
Statut: epublish

Résumé

Patients with Immune-Mediated Inflammatory Diseases (IMIDs) are known to have an elevated risk of developing cancer, but the exact causative factors remain subject to ongoing debate. This narrative review aims to present the available evidence concerning the intricate relationship between these two conditions. Environmental influences and genetic predisposition lead to a dysregulated immune response resulting in chronic inflammation, which is crucial in the pathogenesis of IMIDs and oncogenic processes. Mechanisms such as the inflammatory microenvironment, aberrant intercellular communication due to abnormal cytokine levels, excessive reparative responses, and pathological angiogenesis are involved. The chronic immunosuppression resulting from IMIDs treatments further adds to the complexity of the pathogenic scenario. In conclusion, this review highlights critical gaps in the current literature, suggesting potential avenues for future research. The intricate interplay between IMIDs and cancer necessitates more investigation to deepen our understanding and improve patient management.

Identifiants

pubmed: 39359726
doi: 10.3389/fimmu.2024.1436581
pmc: PMC11445042
doi:

Substances chimiques

Cytokines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1436581

Informations de copyright

Copyright © 2024 Maier, Castiglioni, Petrelli, Cannatelli, Ferretti, Pellegrino, Sarzi Puttini, Fiorina and Ardizzone.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Jeanette A Maier (JA)

Department of Biomedical and Clinical Sciences, Università di Milano, Milano, Italy.

Sara Castiglioni (S)

Department of Biomedical and Clinical Sciences, Università di Milano, Milano, Italy.

Alessandra Petrelli (A)

Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy.

Rosanna Cannatelli (R)

Gastroenterology Unit, ASST Fatebenefratelli-Sacco, Milano, Italy.

Francesca Ferretti (F)

Gastroenterology Unit, ASST Fatebenefratelli-Sacco, Milano, Italy.

Greta Pellegrino (G)

IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milano, Italy.

Piercarlo Sarzi Puttini (P)

Department of Biomedical and Clinical Sciences, Università di Milano, Milano, Italy.
IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milano, Italy.

Paolo Fiorina (P)

Department of Biomedical and Clinical Sciences, Università di Milano, Milano, Italy.

Sandro Ardizzone (S)

Gastroenterology Unit, ASST Fatebenefratelli-Sacco, Milano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH